Ken Griffin Vanda Pharmaceuticals Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 51,500 shares of VNDA stock, worth $253,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,500

Previous 28,300 81.98%

Holding current value

$253,380

Previous $159,000 51.57%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.61 - $6.34 $23,054 - $31,706	-5,001 Reduced 3.39%	142,435 $668,000
Q2 2024 Aug 14, 2024	SELL	$3.91 - $6.5 $2.26 Million - $3.76 Million	-577,803 Reduced 79.67%	147,436 $833,000
Q1 2024 May 15, 2024	BUY	$3.47 - $4.61 $368,628 - $489,734	106,233 Added 17.16%	725,239 $2.98 Million
Q4 2023 Feb 14, 2024	SELL	$3.38 - $4.58 $220,196 - $298,373	-65,147 Reduced 9.52%	619,006 $2.61 Million
Q3 2023 Nov 14, 2023	BUY	$4.28 - $6.57 $208,174 - $319,558	48,639 Added 7.65%	684,153 $2.96 Million
Q2 2023 Aug 14, 2023	SELL	$5.9 - $6.95 $2.26 Million - $2.66 Million	-382,687 Reduced 37.58%	635,514 $4.19 Million
Q1 2023 May 15, 2023	BUY	$6.18 - $7.99 $2.9 Million - $3.75 Million	469,872 Added 85.69%	1,018,201 $6.91 Million
Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $3.16 Million - $5.05 Million	460,594 Added 524.98%	548,329 $4.05 Million
Q3 2022 Nov 14, 2022	BUY	$9.44 - $11.76 $491,427 - $612,202	52,058 Added 145.91%	87,735 $867,000
Q2 2022 Aug 15, 2022	SELL	$9.31 - $11.84 $32,799 - $41,712	-3,523 Reduced 8.99%	35,677 $389,000
Q3 2021 Nov 15, 2021	SELL	$15.35 - $21.27 $1.06 Million - $1.47 Million	-69,324 Reduced 63.88%	39,200 $672,000
Q2 2021 Aug 16, 2021	SELL	$15.71 - $21.51 $999,548 - $1.37 Million	-63,625 Reduced 36.96%	108,524 $2.33 Million
Q1 2021 May 17, 2021	SELL	$13.42 - $20.28 $963,904 - $1.46 Million	-71,826 Reduced 29.44%	172,149 $2.59 Million
Q4 2020 Feb 16, 2021	SELL	$9.77 - $13.81 $6.84 Million - $9.67 Million	-700,360 Reduced 74.16%	243,975 $3.21 Million
Q3 2020 Nov 16, 2020	BUY	$9.32 - $12.02 $468,646 - $604,413	50,284 Added 5.62%	944,335 $9.12 Million
Q2 2020 Aug 14, 2020	BUY	$9.66 - $12.02 $5.72 Million - $7.12 Million	592,275 Added 196.26%	894,051 $10.2 Million
Q1 2020 May 15, 2020	SELL	$7.5 - $16.8 $162,435 - $363,854	-21,658 Reduced 6.7%	301,776 $3.13 Million
Q4 2019 Feb 14, 2020	SELL	$12.38 - $17.47 $1.11 Million - $1.57 Million	-90,007 Reduced 21.77%	323,434 $5.31 Million
Q3 2019 Nov 14, 2019	BUY	$12.27 - $15.79 $4.44 Million - $5.72 Million	361,974 Added 703.31%	413,441 $5.49 Million
Q2 2019 Aug 14, 2019	SELL	$13.37 - $18.85 $988,537 - $1.39 Million	-73,937 Reduced 58.96%	51,467 $725,000
Q1 2019 May 15, 2019	SELL	$17.59 - $31.05 $809 - $1,428	-46 Reduced 0.04%	125,404 $0
Q4 2018 Feb 14, 2019	SELL	$18.97 - $31.47 $5.63 Million - $9.34 Million	-296,849 Reduced 70.29%	125,450 $3.28 Million
Q3 2018 Nov 13, 2018	BUY	$18.25 - $23.0 $5.13 Million - $6.46 Million	280,979 Added 198.82%	422,299 $0
Q2 2018 Aug 10, 2018	BUY	$13.95 - $19.15 $891,488 - $1.22 Million	63,906 Added 82.55%	141,320 $0
Q1 2018 May 11, 2018	SELL	$14.05 - $20.2 $761,313 - $1.09 Million	-54,186 Reduced 41.17%	77,414 $1.3 Million
Q4 2017 Feb 09, 2018	SELL	$12.85 - $18.1 $8.47 Million - $11.9 Million	-658,785 Reduced 83.35%	131,600 $2 Million
Q3 2017 Nov 09, 2017	BUY	$15.4 - $18.85 $12.2 Million - $14.9 Million	790,385	790,385 $14.1 Million

Others Institutions Holding VNDA

# of Institutions

161

Shares Held

45.3M

Call Options Held

165K

Put Options Held

33.6K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $278M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account